Rocket Pharmaceuticals
RCKT
119 hedge funds and large institutions have $1.14B invested in Rocket Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 24 reducing their positions, and 15 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 24
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
53% more capital invested
Capital invested by funds: $744M → $1.14B (+$395M)
11% more funds holding
Funds holding: 107 → 119 (+12)
1.48% more ownership
Funds ownership: 96.87% → 98.35% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$9.29M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$8.88M |
| 5 |
O
OrbiMed
New York
|
+$6.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$29.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.87M |
| 3 |
HM
HealthCor Management
New York
|
-$5.16M |
| 4 |
Morgan Stanley
New York
|
-$4.25M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.33M |
RCKT Hedge Fund Activity: Q2 2020 in Review
119 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2020, worth a combined $1.14B — up 53% from $744M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new RCKT positions and 15 closed out — a net gain of 12 holders — while 48 added to existing stakes and 24 trimmed.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $17.4M. The largest seller was Deerfield Management, cutting an estimated $29.3M.
- 119 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2020, up from 107 in Q1 2020.
- Funds reported $1.14B of Rocket Pharmaceuticals stock for Q2 2020, up 53% quarter-over-quarter.
- 27 funds opened new Rocket Pharmaceuticals positions in Q2 2020 and 15 closed out, a net change of +12 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2020 was Loomis, Sayles & Company, an estimated $17.4M added.
- The largest Rocket Pharmaceuticals seller in Q2 2020 was Deerfield Management, an estimated $29.3M sold.
Based on aggregated 13F filings for Q2 2020.